Building R&D Capabilities In China – Spotlight On Pfizer

SHANGHAI - Multinational pharmaceutical companies have moved beyond debating whether to open R&D operations in China to debating whether to open "brick and mortar" operations or "virtual" operations via outsourcing, according to speakers at the China 2008 Pharmaceutical R&D Summit in Shanghai